Prescient Medicine Holdings and Metabiomics partnered to develop a microbiome diagnostic platform to diagnose gastrointestinal diseases including Crohn's disease, ulcerative colitis and irritable bowel syndrome.
Here's what you should know:
1. The companies expect the test will be available in 2020.
2. The tests detect polyp and carcinogenesis warning signs in the colon.
3. Prescient Medicine CEO and Founder Keri Donaldson said, "These simple yet incredibly powerful tools will dramatically change the equation when it comes to earlier identification of precancerous conditions, leading to early treatment decisions, reduced costs and better outcomes. Metabiomics is an extraordinary partner in our mission to prevent disease and provide the very best care at the lowest possible cost to the healthcare system."